Streptokinase Treatment Reverses Biofilm-Associated Antibiotic Resistance in Staphylococcus aureus.
Biofilms formed by Staphylococcus aureus is a serious complication to the use of medical implants. A central part of the pathogenesis relies on S. aureus' ability to adhere to host extracellular matrix proteins, which adsorb to medical implants and stimulate biofilm formation. Being coagulase positive, S. aureus furthermore induces formation of fibrin fibers from fibrinogen in the blood. Consequently, we hypothesized that fibrin is a key component of the extracellular matrix of S. aureus biofilms under in vivo conditions, and that the recalcitrance of biofilm infections can be overcome by combining antibiotic treatment with a fibrinolytic drug. We quantified S. aureus USA300 biofilms grown on peg-lids in brain heart infusion (BHI) broth with 0%-50% human plasma. Young (2 h) and mature (24 h) biofilms were then treated with streptokinase to determine if this lead to dispersal. Then, the minimal biofilm eradication concentration (MBEC) of 24 h old biofilms was measured for vancomycin and daptomycin alone or in combination with 10 µg/mL rifampicin in the presence or absence of streptokinase in the antibiotic treatment step. Finally, biofilms were visualized by confocal laser scanning microscopy. Addition of human plasma stimulated biofilm formation in BHI in a dose-dependent manner, and biofilms could be partially dispersed by streptokinase. The biofilms could be eradicated with physiologically relevant concentrations of streptokinase in combination with rifampicin and vancomycin or daptomycin, which are commonly used antibiotics for treatment of S. aureus infections. Fibronolytic drugs have been used to treat thromboembolic events for decades, and our findings suggest that their use against biofilm infections has the potential to improve the efficacy of antibiotics in treatment of S. aureus biofilm infections.
Interdisciplinary Nanoscience Center, Aarhus University, 8000 Aarhus C, Denmark. nisjoerg@rm.dk.|Department of Infectious Diseases, Aarhus University Hospital, 8200 Aarhus N, Denmark. nisjoerg@rm.dk.
Nis Pedersen
NP
Jørgensen
Interdisciplinary Nanoscience Center, Aarhus University, 8000 Aarhus C, Denmark. zobeknatalia@gmail.com.
Natalia
N
Zobek
Interdisciplinary Nanoscience Center, Aarhus University, 8000 Aarhus C, Denmark. cd@inano.au.dk.
Cindy
C
Dreier
Department of Veterinary Disease Biology, University of Copenhagen, 1870 Frederiksberg C, Denmark. jhaa@sund.ku.dk.
Jakob
J
Haaber
Department of Veterinary Disease Biology, University of Copenhagen, 1870 Frederiksberg C, Denmark. hi@sund.ku.dk.
Hanne
H
Ingmer
Department of Clinical Biochemistry, Aarhus University Hospital, 8200 Aarhus N, Denmark. ole.halfdan.larsen@clin.au.dk.
Ole Halfdan
OH
Larsen
Interdisciplinary Nanoscience Center, Aarhus University, 8000 Aarhus C, Denmark. rikke.meyer@inano.au.dk.|Department of Bioscience, Aarhus University, 8000 Aarhus C, Denmark. rikke.meyer@inano.au.dk.
Rikke L
RL
Meyer
MBEC; USA300; biofilm; fibrinolysis; human plasma
Infect Immun. 2002 Dec;70(12):6680-7
12438342
Front Cell Infect Microbiol. 2014 Dec 23;4:178
25566513
Science. 1987 Sep 25;237(4822):1588-95
3629258
Nat Rev Microbiol. 2014 Jan;12(1):49-62
24336184
Antimicrob Agents Chemother. 2012 Dec;56(12):6310-8
23027191
J Antibiot (Tokyo). 2012 Feb;65(2):73-7
22167157
Infect Immun. 2005 Aug;73(8):4596-606
16040971
Trends Microbiol. 2013 Sep;21(9):466-74
23827084
Annu Rev Med. 2013;64:175-88
22906361
Clin Infect Dis. 2009 Aug 1;49(3):325-7
19569969
J Infect Dis. 2013 Jul;208(1):92-100
23532100
EMBO J. 2002 Dec 16;21(24):6660-72
12485987
Mol Microbiol. 2007 Feb;63(3):711-23
17302800
J Antimicrob Chemother. 2010 Sep;65(9):1955-8
20615927
Mol Microbiol. 2002 May;44(4):1033-44
12010496
PLoS One. 2014 Nov 19;9(11):e112730
25409527
J Exp Med. 1950 Feb 28;91(3):295-307
19871706
Infect Immun. 2000 Dec;68(12):6871-8
11083807
Virulence. 2011 Sep-Oct;2(5):445-59
21921685
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2601-9
26856841
J Biol Chem. 2011 Jul 22;286(29):25963-72
21543319
Antimicrob Agents Chemother. 2006 Oct;50(10):3245-9
17005801
Trends Microbiol. 2011 May;19(5):225-32
21353779
Curr Med Res Opin. 1991;12(8):479-84
1764952
J Clin Microbiol. 2013 Jul;51(7):2131-8
23616460
J Clin Microbiol. 1999 Jun;37(6):1771-6
10325322
Appl Environ Microbiol. 2015 Oct 30;82(1):394-401
26519394
Antimicrob Agents Chemother. 2005 Jun;49(6):2467-73
15917548
Clin Infect Dis. 2015 Mar 1;60(5):741-9
25389255
Appl Microbiol Biotechnol. 2007 May;75(1):125-32
17221196
J Infect Dis. 2016 Jan 1;213(1):139-48
26136471
FEMS Microbiol Lett. 2014 Apr;353(2):157-64
24628034
Front Cell Infect Microbiol. 2015 Jan 28;5:1
25674541
Antimicrob Agents Chemother. 2013 Apr;57(4):1998-2000
23403427
FEMS Immunol Med Microbiol. 2008 Jan;52(1):13-22
18081847
Antimicrob Agents Chemother. 2009 Jul;53(7):3166-9
19451302
Future Microbiol. 2011 Nov;6(11):1329-49
22082292
EMBO J. 2005 Dec 21;24(24):4224-36
16362049
Circulation. 2010 Mar 9;121(9):1141-52
20212293
J Biol Chem. 2016 Aug 26;291(35):18148-62
27387503
Elife. 2015 Jun 02;4:null
26032562
BMC Res Notes. 2014 Jul 17;7:457
25034276
J Orthop Res. 2012 Jul;30(7):1176-80
22228044
Methods Mol Biol. 2014;1147:203-13
24664835
Int J Antimicrob Agents. 2013 Jun;41(6):521-3
23611308
J Infect Dis. 2015 Dec 15;212(12):1883-93
26044292
Chemotherapy. 2000 Mar-Apr;46(2):111-5
10671761
Perit Dial Int. 2010 Nov-Dec;30(6):652-6
21148059
Proteomics. 2006 Mar;6(6):1867-77
16470655